| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
Purity: ≥98%
Tobramycin Sulfate (Tobraneg; Dartobcin; Deoxykanamycin B; Nebcine; Tobrasix), the sulfate salt of Tobramycin, is a potent, broad-spectrum and aminoglycoside antibiotic that binds to 70S ribosomal subunit, inhibits translocation and elicits miscoding. Tobramycin is produced by Streptomyces tenebrarius and is effective against gram-negative bacteria, and especially potent against the Pseudomonas species.
| ln Vitro |
When tobramycin was combined with vancomycin, tobramycin itself and the increase of its incorporated dose had an influence on the elution kinetics of both antibiotics but not vice versa [1]
When an aminoglycoside (gentamicin or tobramycin) has been combined with vancomycin, in vitro studies have demonstrated a synergistic effect for one or both agents which is maintained in cement when both drugs are released in active form at site of infection. [1] |
|---|---|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Summary of Tobramycin Use During Lactation Tobramycin is rarely excreted into breast milk. Newborns appear to absorb small amounts of other aminoglycoside antibiotics, but even with three-times daily dosing, serum concentrations are far lower than those achieved when treating neonatal infections, making systemic effects of tobramycin unlikely. Even less tobramycin is expected to be absorbed by older infants. Because the concentration of tobramycin in breast milk fluctuates very little with multiple-dose regimens, adjusting the timing of breastfeeding and administration offers little benefit in reducing infant exposure. There are currently no data for single-dose daily regimens. Monitoring for potential effects on the infant's gut microbiota, such as diarrhea, candidiasis (e.g., thrush, diaper rash), or rare hematochezia (suggesting possible antibiotic-associated colitis), should be conducted. The risk to breastfeeding infants is minimal or nonexistent for mothers using ear or eye drops containing tobramycin. A working group of respiratory specialists from Europe, Australia, and New Zealand found that inhaled tobramycin is compatible with breastfeeding. ◉ Effects on Breastfed Infants An infant was exclusively breastfed for the first 4 months postpartum (expansion not specified). At 2 months of age, the mother received a 2-week course of tobramycin (150 mg three times daily) for an acute exacerbation of cystic fibrosis, concurrently with meropenem. During the mother's treatment, the infant's bowel habits remained unchanged, and renal function was normal at 6 months of age. ◉ Effects on Lactation and Breast Milk As of the revision date, no relevant published information was found. |
| References |
Biomed Res Int. 2017;2017:4657874.
|
| Additional Infomation |
See also: Tobramycin sulfate (note moved to).
|
| Molecular Formula |
C18H37N5O9.H2O4S
|
|---|---|
| Molecular Weight |
565.59296
|
| Exact Mass |
565.226
|
| CAS # |
79645-27-5
|
| Related CAS # |
32986-56-4(Tobramycin)
|
| PubChem CID |
54413
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
775.4ºC at 760 mmHg
|
| Flash Point |
422.8ºC
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
37
|
| Complexity |
691
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
NC[C@@H]1[C@@H](O)C[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3C[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)O1
|
| InChi Key |
ZEUUPKVZFKBXPW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H37N5O9.H2O4S/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18;1-5(2,3)4/h5-18,24-28H,1-4,19-23H2;(H2,1,2,3,4)
|
| Chemical Name |
4-amino-2-[4,6-diamino-3-[3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid
|
| Synonyms |
Tobraneg; Nebramycin Factor 6; Dartobcin; Deoxykanamycin B; Tobramycin Sulfate; Nebcine; Tobrasix;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7681 mL | 8.8403 mL | 17.6807 mL | |
| 5 mM | 0.3536 mL | 1.7681 mL | 3.5361 mL | |
| 10 mM | 0.1768 mL | 0.8840 mL | 1.7681 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT03066453
Conditions:Cystic FibrosisLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006215-68
Condition:cystic fibrosis and P. aeruginosa chronic infectionProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA